Latest Content

Revisyon is described as a device-led therapy that applies specific wavelengths of low-level LED light to the crystalline lens through a non-invasive, in-clinic procedure.

This research is part of the IIH Research and Treatment Initiative, a new philanthropy-funded program launched at Mass General Brigham.

Formerly known as Brimochol PF, the dual-agent eye drop is now the first and only of its kind for the treatment of presbyopia in adults.

This enables the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU).

The investigators evaluated the shear-stress-dependent viscous properties of seven commercially available tear formulations. They also studied the viscosity of natural tears.

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

Two recent journal articles underscore the organ’s importance in identifying systemic disease processes.

The study looked at 128 eyes in 64 patients before and after they had received the vaccine.

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Lens thickness and ciliary muscle are not affected by low-dose pilocarpine.

Benjamin P. Casella, OD, FAAO, shares perspectives on the most impactful glaucoma developments from the past year and the future role of interventional and personalized care.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.